Search for:

Search Medicine or Company Name Search Full Document

Advanced Search

Archimedes Pharma UK Ltd
250 South Oak Way, Green Park, Reading, RG2 6UG, UK Telephone: +44 (0)118 931 5050 Fax: +44 (0)118 931 5056 WWW: http://www.archimedespharma.com Need to contact this company?

Summary of Product Characteristics last updated on the eMC: 21/10/2009

SPC	Cobalin-H injection

Table of Contents

1. NAME OF THE MEDICINAL PRODUCT
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
3. PHARMACEUTICAL FORM
4. CLINICAL PARTICULARS
4.1 Therapeutic indications
4.2 Posology and method of administration
4.3 Contraindications
4.4 Special warnings and precautions for use
4.5 Interaction with other medicinal products and other forms of interaction
4.6 Pregnancy and lactation
4.7 Effects on ability to drive and use machines
4.8 Undesirable effects
4.9 Overdose
5. PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties
5.2 Pharmacokinetic properties
5.3 Preclinical safety data
6. PHARMACEUTICAL PARTICULARS
6.1 List of excipients
6.2 Incompatibilities
6.3 Shelf life
6.4 Special precautions for storage
6.5 Nature and contents of container
6.6 Special precautions for disposal and other handling
7. MARKETING AUTHORISATION HOLDER
8. MARKETING AUTHORISATION NUMBER(S)
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
10. DATE OF REVISION OF THE TEXT

Go to top of the page

1. NAME OF THE MEDICINAL PRODUCT

Cobalin-H

Go to top of the page

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Anhydrous hydroxocobalamin 1000mcg/ml

Go to top of the page

3. PHARMACEUTICAL FORM

Injection

Go to top of the page

4. CLINICAL PARTICULARS

Go to top of the page

4.1 Therapeutic indications

Treatment of Addisonian pernicious anaemia.

Prophylaxis and treatment of other macrocytic anaemias due to vitamin B₁₂ deficiency.

Treatment of tobacco amblyopia.

Treatment of Leber's atrophy.

Go to top of the page

4.2 Posology and method of administration

The following dosages are suitable for children and adults.

Addisonian pernicious anaemia and other macrocytic anaemias without neurological involvement:

Initially:	250 micrograms to 1000 micrograms intramuscularly on alternate days for one or two weeks then 250 micrograms weekly until blood count is normal.
Maintenance:	1000 micrograms every two or three months.

Addisonian pernicious anaemia and other macrocytic anaemias with neurological involvement:

Initially:	1000 micrograms by intramuscular injection on alternate days as long as improvement continues.
Maintenance:	1000 micrograms every two months.

Prophylaxis of macrocytic anaemias associated with vitamin B₁₂ deficiency resulting from gastrectomy, ileal resection, certain malabsorption states and vegetarianism:

1000 micrograms every two or three months.

Tobacco amblyopia and Leber's optic atrophy:

Initially:	1000 micrograms daily by intramuscular injection for two weeks then twice weekly as long as improvement is maintained.
Maintenance:	1000 micrograms every three months or as required.

Go to top of the page

4.3 Contraindications

Sensitivity to hydroxocobalamin / vitamin B₁₂.

Go to top of the page

4.4 Special warnings and precautions for use

Cobalin-H should not be given before a megaloblastic marrow has been demonstrated. Regular monitoring of the blood is advisable. Doses of hydroxocobalamin greater than 10 micrograms daily may produce a haematological response in patients with folate deficiency. Indiscriminate use may mask the exact diagnosis. Cardiac arrhythmias secondary to hypokalaemia have been reported during initial therapy and plasma potassium should, therefore, be monitored during this period.

Go to top of the page

4.5 Interaction with other medicinal products and other forms of interaction

The serum concentration of hydroxocobalamin may be reduced by concurrent administration of oral contraceptives. Chloramphenicol-treated patients may respond poorly to hydroxocobalamin. Vitamin B₁₂ assays by microbiological techniques are invalidated by antimetabolites and most antibiotics.

Go to top of the page

4.6 Pregnancy and lactation

Hydroxocobalamin should not be used to treat megaloblastic anaemia of pregnancy.

Go to top of the page

4.7 Effects on ability to drive and use machines

None stated.

Go to top of the page

4.8 Undesirable effects

The following effects have been reported and are listed below by body system:

Disorders of the immune system:

Rare: Allergic hypersensitivity reactions

Very Rare: Anaphylaxis

Gastro intestinal disorders:

Frequency Not Known: Nausea

General disorders :

Frequency Not Known: Fever, dizziness, Injection site disorders

Neurological disorders:

Frequency Not Known: Headache

Go to top of the page

4.9 Overdose

Treatment is unlikely to be needed in cases of overdosage.

Go to top of the page

5. PHARMACOLOGICAL PROPERTIES

Go to top of the page

5.1 Pharmacodynamic properties

Vitamin B₁₂

ATC classification: B03B A03

Go to top of the page

5.2 Pharmacokinetic properties

Vitamin B₁₂ is extensively bound to specific plasma proteins called transcobalamins; transcobalamin II appears to be involved in the rapid transport of the cobalamins to tissues. It is stored in the liver, excreted in the bile, and undergoes enterohepatic recycling; part of a dose is excreted in the urine, most of it in the first 8 hours.

Go to top of the page

5.3 Preclinical safety data

There are no preclinical data of relevance to the prescriber which are additional to that already included in other sections of the Summary of Product Characteristics.

Go to top of the page

6. PHARMACEUTICAL PARTICULARS

Go to top of the page

6.1 List of excipients

Sodium dihydrogen orthophosphate

Sodium chloride

Water for Injections

Go to top of the page

6.2 Incompatibilities

None stated.

Go to top of the page

6.3 Shelf life